Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Breast 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Primary Myelofibrosis 23Myeloproliferative Disorders 15Leukemia, Myeloid, Acute 14Polycythemia Vera 10Leukemia 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Myelodysplastic Syndromes 9Graft vs Host Disease 8Thrombocythemia, Essential 7Recurrence 6Neoplasms 6Lymphoma, T-Cell 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Breast Neoplasms 4Prostatic Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Prolymphocytic, T-Cell 3Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Bronchiolitis Obliterans Syndrome 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Multiple Myeloma 2

Interventions

Bevacizumab 119Fluorouracil 91Leucovorin 83Cetuximab 83Oxaliplatin 80pembrolizumab 70Irinotecan 67Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26Standard of Care 25HMPL-013 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19atezolizumab 18Trifluridine 18Cisplatin 18tislelizumab 17balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Colorectal Neoplasms × ruxolitinib × 1 year × Clear all
NCT07566897 2026-05-05

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

Philogen S.p.A.

Phase 1 Not yet recruiting
96 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02955940 2025-12-17

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Incyte Corporation

Phase 2 Active not recruiting
10 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡